Linked Life Data

15054673

Source:http://linkedlifedata.com/resource/pubmed/id/15054673

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-9-29
pubmed:abstractText
Ondansetron has been used widely in plastic surgery to prevent postoperative nausea and vomiting. A literature search showed controversial dosages of this drug, and because of its short half-life, its use only before anesthetic induction could have a limited effect. The purpose of this study was to assess the efficacy of intravenous (IV) ondansetron (4 mg) for aesthetic plastic surgery performed with the patient under general anesthesia and the prophylaxis of postoperative nausea and vomiting (PONV) in two situations: (a) only before anesthetic induction and (b) before anesthetic induction and immediately before extubation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0364-216X
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
33-6
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Ondansetron for the prevention of postoperative nausea and vomiting: which is the best dosage for aesthetic plastic surgery?
pubmed:affiliation
São Paulo, SP / Brazil. drmbarbosa@ig.com.br
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial